Corbus Pharmaceuticals Holdings Inc CRBP

NAS: CRBP | ISIN: US21833P1030   3/05/2024
38,77 USD (+1,49%)
(+1,49%)   3/05/2024

27 september 2023 · Corbus Pharmaceuticals to Present Latest Pre-Clinical Data on its Anti-aVb8 Monoclonal Antibody (CRB-601) at the 2023 SITC Annual Meeting · Persbericht

19 september 2023 · Corbus Pharmaceuticals to Present Pre-Clinical Data Characterizing its CRB-701 Nectin-4 ADC at the at AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics · Persbericht

8 augustus 2023 · Corbus Pharmaceuticals Reports Second Quarter 2023 Financial Results and Provides Corporate Update · Persbericht

31 juli 2023 · Corbus Pharmaceuticals to Present at the BTIG Virtual Biotechnology Conference · Persbericht

26 juni 2023 · Corbus Pharmaceuticals Set to Join Russell Microcap® Index · Persbericht

31 mei 2023 · Corbus Pharmaceuticals to Participate in the 2023 Jefferies Healthcare Conference · Persbericht

9 mei 2023 · Corbus Pharmaceuticals Reports First Quarter 2023 Financial Results and Provides Corporate Update · Persbericht

1 mei 2023 · Corbus Pharmaceuticals to Present Latest Pre-Clinical Data on CRB-601 avβ8 Blocking Antibody at the New York Academy of Sciences' Frontiers in Cancer Immunotherapy Meeting · Persbericht

18 april 2023 · Corbus Pharmaceuticals Hosting Virtual 'Meet the Expert' Series: Blocking TGFβ with CRB-601--a New Play for an Old Target · Persbericht

17 april 2023 · Corbus Pharmaceuticals Presents Latest Pre-Clinical Data on CRB-601 at the 2023 American Association for Cancer Research Annual Meeting · Persbericht

14 maart 2023 · Corbus Pharmaceuticals Data on CRB-601 avβ8 Blocking Antibody Accepted for Presentation at the America Association for Cancer Research Annual Meeting · Persbericht

7 maart 2023 · Corbus Pharmaceuticals Reports Fourth Quarter 2022 and Year-End Financial Results and Provides Corporate Update · Persbericht

6 maart 2023 · Corbus Pharmaceuticals Expands Board of Directors with Appointment of Yong Ben, M.D., MBA · Persbericht

2 maart 2023 · Corbus Pharmaceuticals to Present at the Oppenheimer 33rd Annual Healthcare Conference · Persbericht

13 februari 2023 · Corbus Pharmaceuticals expands oncology pipeline with the addition of a clinical stage Nectin-4 targeting Antibody Drug Conjugate (ADC) · Persbericht

10 november 2022 · Corbus Presents Latest Preclinical Data for CRB-601 at the Society for Immunotherapy of Cancer (SITC) 37th Annual Meeting · Persbericht

8 november 2022 · Corbus Pharmaceuticals Reports Third Quarter 2022 Financial Results and Provides Corporate Update · Persbericht

14 oktober 2022 · Corbus Pharmaceuticals to Present Pre-Clinical Data for CRB-601 at the Society for Immunotherapy of Cancer (SITC) 37th Annual Meeting · Persbericht

26 september 2022 · Corbus Pharmaceuticals Appoints Anne Altmeyer, PhD to Board of Directors · Persbericht

22 september 2022 · Corbus Presents First Pre-Clinical Data for CRB-913 at the European Association for the Study of Diabetes 2022 Annual Conference · Persbericht

Mijn selecties